Patterson Companies upgraded to Buy from Neutral at UBS Following its global dental survey, UBS upgraded Patterson Companies to reflect expectations for an increase in U.S. dental patient volumes and notes its discounted valuation vs. its peer group. Price target raised to $43 from $39.
News For PDCO From The Last 14 Days
Check below for free stories on PDCO the last two weeks.
Patterson Companies reports Q1 EPS 50c, consensus 50c Reports Q1 revenue $1.06B, consensus $1.04B. 1Q15 results included $173.6M of consolidated sales and an earnings contribution of 2c per diluted share from the acquisition in the United Kingdom of National Veterinary Services Limited, which closed on August 16, 2013.